Opening Recap
Market Pulse Memecoins set the tone yesterday as MemeCore [M] ripped 16% on a flood of retail FOMO, pushing risk appetite back into the red-hot zone. That one-day surge left the broader market bristling for more after a modest pullback.
Key Movers FedEx saw trading volumes spike after delivering a blowout earnings report, while Goldman Sachs bumped its outlook on Braze following a solid quarter. These two corporate beats outshined everything else on the tape.
Macro & Politics Trump’s latest cannabis rescheduling saga surfaced in Part II of the series, promising fresh catalysts and looming legislative curveballs. On the same front, Pfizer’s public feint against the former president is getting laughed off by five industry vets, but PR skirmishes can still jitter sentiment.
What’s Next Keep eyes locked on memecoins for another short-squeeze pulse, biotech names riding FDA verdicts, and politically charged tickers dancing in regulatory headlines.
Market Commentary
What's being overlooked is the hangover risk after that 16% MemeCore ramp (MemeCore [M] booms 16% as memecoins surge, Ambcrypto.com). Retail traders are piling in as though every pump is proof of infinite upside, ignoring that volume spiked and can vanish even faster. Meanwhile, biotech catalysts—like the Orland Park gene therapy for Barth syndrome (Orland Park baby’s treatment for rare genetic disease Barth Syndrome granted accelerated approval, WLS-TV)—offer more tangible next legs, but no one’s paying attention because meme headlines are sexier. That mix of fleeting crypto frenzy and underplayed biotech jams up a risk trade that could unravel in minutes.
It’s funny how the cannabis rescheduling chatter (Part II: Trump And Cannabis Rescheduling: Opportunities And Limitations Under Rescheduling, Forbes) and Pfizer’s public smackdown over Trump’s Covid jab data (5 Reasons Pfizer’s Reply to President Trump Is Complete Rubbish, Activistpost.com) are dancing on the same regulatory tightrope. On one hand, you’ve got potential 280E tax relief and DEA regrouping that could rewire state markets; on the other, pharma’s public punditry is a political sideshow that can rip valuations to bits on a rumor. Link those to Merck’s Keytruda QLEX greenlight (Merck announces FDA approval of Keytruda Qlex, Thefly.com) and you see a policy-driven triangle where genre-bending regulation dictates pockets of extreme volatility.
Action time: position yourself for microflares, not macro binges. Lock down stop-losses on memecoins and any biotech here solely for the FDA stamp play, and size up FedEx (FedEx (NYSE:FDX) Sees Large Volume Increase After Earnings Beat, ETF Daily News) and Braze (Goldman Sachs Lifts Braze (BRZE) PT to $52, Reports Strong FQ2 2026 Earnings, Yahoo Entertainment) as classic beat-and-run setups. If you nail entry before policy whispers or the next earnings drop, you’ll avoid the garbage dumps too many buy into once the crowd rushes in.
📈 Breaking Financial News
FedEx (NYSE:FDX) Sees Large Volume Increase After Earnings Beat
FedEx Corporation (NYSE:FDX – Get Free Report) shares saw an uptick in trading volume on Friday following a stronger than expected earnings report. 3,126,218 shares were traded during mid-day trading, an increase of 57% from the previous session’s volume of 1…
Merck announces FDA approval of Keytruda Qlex
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corpor…
Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’
We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday.
Replimune extended losses to a second consecutive day on Thursday, slashing 39.40 percent to close at $3.46 apiece aft…
Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’
We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the best performers on Thursday. Replimune…
MemeCore [M] booms 16% as memecoins surge: Will the rally last?
Bullish pressure faces threat from volume.
Terrifying reason Trump killed the U.S. penny?
You see, the U.S. is facing a looming shortage that could cripple the economy with runaway inflation… and send one tiny clutch of investments soaring in the weeks ahead. Former White House Advisor, Jim Rickards, just came forward to share this startling story.
🔍 Market Analysis & Insights
Part II: Trump And Cannabis Rescheduling: Opportunities And Limitations Under Rescheduling
Part II of our cannabis rescheduling series explores Trump’s impact, Big Pharma myths, 280E tax relief, DEA registration, state markets, and global trade.
Amgen Attacks Academics’ False Claims About Biologic Patents
The ongoing policy debate about pharmaceutical and biologic patents has been coopted by those who don’t like patents—including those who have a financial incentive not to like patents. These paid mercenaries concoct and then disseminate fraudulent “reports”, …
Pfizer Inc. (PFE) Pushes Forward in Cancer and Hemophilia Treatments
In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Pfizer Inc. is one of them. Pfizer Inc. (NYSE:PFE), a global…
3 market experts tell us why they're skeptical about retail traders' favorite meme stock
Eric Jackson has set an $82 price target for Opendoor. Some investors see that as too bullish given fundamentals and the state of the housing market.
Goldman Sachs Lifts Braze (BRZE) PT to $52, Reports Strong FQ2 2026 Earnings
Braze Inc. (NASDAQ:BRZE) is one of the best enterprise software stocks to buy according to analysts. On September 7, Goldman Sachs raised the firm’s price…
The Real Reason 218,000 Acres Just Vanished
The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake. Find out why this could be the most lucrative “underground” energy story in America – click here.
💰 Investment Opportunities
5 Reasons Pfizer’s Reply to President Trump Is Complete Rubbish
On September 1, 2025, on Truth Social, President Trump posted a demand for transparency. Specifically, he called for public release of the data he has received from pharmaceutical companies regarding the modified-mRNA-based Covid injections, calling out Pfize…
Orland Park baby's treatment for rare genetic disease Barth Syndrome granted accelerated approval by Food and Drug Administration
A baby in the Chicago area is battling a rare disease and desperately needs a drug treatment for a better life. The drug has now been granted accelerated approval by the FDA.
Edwards Lifesciences Corporation (EW): A Bull Case Theory
We came across a bullish thesis on Edwards Lifesciences Corporation on Natan’s Substack. In this article, we will summarize the bulls’ thesis on EW. Edwards …
Scotiabank Lifts Telus International (TIXT) Price Target on TELUS Digital Merger Plans
Telus International (NYSE:TIXT) is one of the best AI stocks to buy under $5. On September 4, Scotiabank raised the stock’s price target to $4.50 from $3.50….
H&R Block, Inc. (HRB): A Bull Case Theory
We came across a bullish thesis on H&R Block, Inc. on X.com by FishtownCap. In this article, we will summarize the bulls’ thesis on HRB. H&R Block, Inc.’s…
Please read this now. Urgent opportunity.
Larry Benedict says it's “the most consistently profitable method he's ever seen”… He calls it “Bitcoin Skimming”… It doesn't involve buying or selling Bitcoin at all. You don't need to invest a single penny in any cryptocurrency.